Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
The GLP-1/GIP dual agonist, HRS9531, from Hengrui, reported positive Phase 3 results in weight loss, and is the second (after Innovent) Chinese company to submit marketing authorisation for an obesity asset
Elecoglipron produced clear dose-dependent reductions in body weight
However, only 41.8% stayed on treatment at 6 months 109 , in line with the available literature reporting disappointingly low adherence to liraglutide for obesity management and raising concerns about its role in the lifelong challenge of BW control and weight-related complications 110
This bioavailable BPC formula delivers a precise micro-dose to help maintain cellular signaling involved in repair and resilience, offering focused gut health support alongside joint and muscle support
US$ 26.87
US$ 26.46
US$ 28.57
US$ 21.29
US$ 26.83
US$ 21.19
